$NTRA
Natera, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007686 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $413.4M $367.7M
YoY Change 58.13% 52.11%
Cost Of Revenue $170.2M $159.1M
YoY Change 18.88% 7.44%
Gross Profit $243.2M $208.6M
YoY Change 105.63% 122.79%
Gross Profit Margin 58.83% 56.72%
Selling, General & Admin $198.0M $194.3M
YoY Change 29.81% 29.84%
% of Gross Profit 81.41% 93.13%
Research & Development $89.11M $88.64M
YoY Change 13.99% 7.69%
% of Gross Profit 36.64% 42.49%
Depreciation & Amortization $7.915M $7.063M
YoY Change 54.47% 39.12%
% of Gross Profit 3.25% 3.39%
Operating Expenses $287.1M $282.9M
YoY Change 24.45% 21.98%
Operating Profit -$43.90M -$74.31M
YoY Change -60.95% -46.27%
Interest Expense $3.127M $3.124M
YoY Change -198.43% 2.06%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$36.57M -$67.17M
YoY Change -67.08% -50.89%
Income Tax $892.0K $428.0K
% Of Pretax Income
Net Earnings -$37.46M -$67.60M
YoY Change -66.19% -50.62%
Net Earnings / Revenue -9.06% -18.38%
Basic Earnings Per Share -$0.30 -$0.56
Diluted Earnings Per Share -$0.30 -$0.56
COMMON SHARES
Basic Shares Outstanding 122.8M 120.8M
Diluted Shares Outstanding 122.9M 120.8M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $887.1M $882.9M
YoY Change 20.54% 8.73%
Cash & Equivalents $796.8M $813.8M
Short-Term Investments $90.30M $69.12M
Other Short-Term Assets $37.80M $46.73M
YoY Change 40.94% 55.84%
Inventory $40.99M $43.02M
Prepaid Expenses
Receivables $335.9M $288.7M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.302B $1.261B
YoY Change 22.18% 11.68%
LONG-TERM ASSETS
Property, Plant & Equipment $133.3M $125.8M
YoY Change -19.16% 25.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.31M $26.42M
YoY Change 67.32% 36.96%
Total Long-Term Assets $215.2M $206.8M
YoY Change 17.98% 9.16%
TOTAL ASSETS
Total Short-Term Assets $1.302B $1.261B
Total Long-Term Assets $215.2M $206.8M
Total Assets $1.517B $1.468B
YoY Change 21.56% 11.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.10M $26.04M
YoY Change 56.82% -27.92%
Accrued Expenses $166.3M $163.8M
YoY Change 15.29% 14.06%
Deferred Revenue $18.37M $17.71M
YoY Change 17.41% 6.79%
Short-Term Debt $80.40M $80.40M
YoY Change -0.02% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $314.6M $305.9M
YoY Change 13.62% 5.15%
LONG-TERM LIABILITIES
Long-Term Debt $283.6M $283.3M
YoY Change 0.46% 0.46%
Other Long-Term Liabilities $82.29M $84.87M
YoY Change -11.13% -11.0%
Total Long-Term Liabilities $365.9M $368.1M
YoY Change -2.4% -2.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $314.6M $305.9M
Total Long-Term Liabilities $365.9M $368.1M
Total Liabilities $680.5M $674.1M
YoY Change 4.41% 0.87%
SHAREHOLDERS EQUITY
Retained Earnings -$2.500B -$2.400B
YoY Change 13.64% 14.29%
Common Stock $3.320B $3.241B
YoY Change 18.77% 18.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $836.5M $794.1M
YoY Change
Total Liabilities & Shareholders Equity $1.517B $1.468B
YoY Change 21.56% 11.32%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$37.46M -$67.60M
YoY Change -66.19% -50.62%
Depreciation, Depletion And Amortization $7.915M $7.063M
YoY Change 54.47% 39.12%
Cash From Operating Activities $3.990M $27.00M
YoY Change -105.09% -133.38%
INVESTING ACTIVITIES
Capital Expenditures $11.68M $20.32M
YoY Change 30.22% 75.16%
Acquisitions
YoY Change
Other Investing Activities -$20.38M $169.1M
YoY Change -136.38% 520.42%
Cash From Investing Activities -$32.05M $138.3M
YoY Change -168.15% 783.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.04M 6.466M
YoY Change 18.6% 181.01%
NET CHANGE
Cash From Operating Activities 3.990M 27.00M
Cash From Investing Activities -32.05M 138.3M
Cash From Financing Activities 11.04M 6.466M
Net Change In Cash -17.02M 171.7M
YoY Change -22.78% -372.85%
FREE CASH FLOW
Cash From Operating Activities $3.990M $27.00M
Capital Expenditures $11.68M $20.32M
Free Cash Flow -$7.688M $6.686M
YoY Change -91.2% -107.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122234000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119581000
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604821
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120814000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111767000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37478
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
CY2024Q1 dei City Area Code
CityAreaCode
650
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
980-9190
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
NTRA
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
122802694
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
813817000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69121000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236882000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7252000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6481000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
288748000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2024Q1 us-gaap Inventory Net
InventoryNet
43024000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40759000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46734000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60524000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1261444000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1258549000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125791000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54553000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
56537000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26417000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15403000
CY2024Q1 us-gaap Assets
Assets
1468205000
CY2023Q4 us-gaap Assets
Assets
1441699000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
26038000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14998000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39577000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45857000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
142228000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17705000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
80401000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80402000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
305949000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
307274000
CY2024Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
283273000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
282945000
CY2024Q1 ntra Contract With Customer And Other Liabilities Noncurrent
ContractWithCustomerAndOtherLiabilitiesNoncurrent
20712000
CY2023Q4 ntra Contract With Customer And Other Liabilities Noncurrent
ContractWithCustomerAndOtherLiabilitiesNoncurrent
19128000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64160000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2024Q1 us-gaap Liabilities
Liabilities
674094000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2301000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
CY2023Q4 us-gaap Liabilities
Liabilities
676372000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
122234000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119581000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3241326000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3145837000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2445035000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2377436000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2192000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
794111000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1468205000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1441699000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
367741000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88637000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82306000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
194278000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149627000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
442055000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
380057000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-74314000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-138301000
CY2024Q1 us-gaap Interest Expense
InterestExpense
3124000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3061000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10267000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4585000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67171000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136777000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
428000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
160000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-67599000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-136937000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
893000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4564000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66706000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132373000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120814000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111767000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5134000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40695000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4564000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-136937000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
650573000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6466000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64952000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
24071000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
893000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-67599000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
794111000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-67599000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-136937000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7063000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5077000
CY2023Q1 ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
2679000
CY2024Q1 ntra Premium Amortization And Discount Accretion On Investment Securities
PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities
-460000
CY2023Q1 ntra Premium Amortization And Discount Accretion On Investment Securities
PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities
787000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
64447000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
40477000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3593000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3806000
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
328000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
320000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-359000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265000
CY2024Q1 ntra Non Cash Interest Expense
NonCashInterestExpense
-1000
CY2023Q1 ntra Non Cash Interest Expense
NonCashInterestExpense
48000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10459000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2400000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2265000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5277000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14428000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2338000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10732000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5762000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
17789000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
14993000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4122000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2177000
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7625000
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-18181000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
793000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7312000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27001000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81108000
CY2024Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
169065000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
27250000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20315000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11380000
CY2024Q1 ntra Payments To Acquire Assets
PaymentsToAcquireAssets
10495000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
138255000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15870000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6466000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2301000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6466000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2301000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
171722000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-62937000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
813817000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403154000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1179000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1124000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
112000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1613000
CY2024Q1 ntra Acquisition Of Warrants
AcquisitionOfWarrants
1884000
CY2023Q1 us-gaap Stock Issued1
StockIssued1
14435000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
24071000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
CY2024Q1 ntra Stock Based Compensation Included In Capitalized Software Development Costs
StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts
505000
CY2023Q1 ntra Stock Based Compensation Included In Capitalized Software Development Costs
StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts
218000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-67600000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2400000000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
813800000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
69100000
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
80400000
CY2024Q1 us-gaap Debt Instrument Collateral Amount
DebtInstrumentCollateralAmount
150000000.0
CY2024Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
20000000.0
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
55
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235800000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p>
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2192000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11798000
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, and restricted cash, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the three months ended March 31, 2024, and 2023, there were no customers exceeding 10% of total revenues on an individual basis. As of March 31, 2024 and December 31, 2023, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the three months ended March 31, 2024 and 2023, approximately 11.6% and 14.1%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. As of March 31, 2024 and December 31, 2023, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">approximately 11.9% and 10.2%, respectively, of accounts receivable are expected to be paid by Medicare on behalf of multiple customers.</p>
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1300000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
367741000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
367741000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
288748000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17705000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18828000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19128000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36533000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2024Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
7941000
CY2023Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
12100000
CY2024Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-7048000
CY2023Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-3988000
CY2024Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-100000
CY2023Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-800000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36533000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38090000
CY2024Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-7000000.0
CY2024Q1 ntra Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis
884826000
CY2024Q1 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Gain
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain
1000
CY2024Q1 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss
1889000
CY2024Q1 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
882938000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis
CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis
881708000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Gain
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain
14000
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
158000
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
7252000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss
CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss
2745000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
878977000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
813817000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
69121000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
236882000
CY2024Q1 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
882938000
CY2023Q4 ntra Cash Cash Equivalents Restricted Cash And Securities
CashCashEquivalentsRestrictedCashAndSecurities
878977000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
14
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
65687000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1889000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
52960000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
52032000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
18049000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
17089000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
71009000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
69121000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6481000
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3830000
CY2024Q1 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-929000
CY2023Q1 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1304000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
184523000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
167503000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58732000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
56293000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125791000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
CY2024Q1 us-gaap Depreciation
Depreciation
6300000
CY2023Q1 us-gaap Depreciation
Depreciation
5100000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18023000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2024Q1 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
13167000
CY2023Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
14823000
CY2024Q1 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
17880000
CY2023Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
11229000
CY2024Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
9688000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10085000
CY2024Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
7050000
CY2024Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
34141000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
43897000
CY2024Q1 ntra Accrued Shipping Charges
AccruedShippingCharges
1652000
CY2023Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
3646000
CY2024Q1 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
4329000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
3731000
CY2024Q1 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
7764000
CY2023Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
7111000
CY2024Q1 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
6961000
CY2023Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
12126000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11957000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2024Q1 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
4429000
CY2023Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
4316000
CY2024Q1 ntra Accrued Interest
AccruedInterest
2695000
CY2023Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2024Q1 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
2492000
CY2023Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
2497000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
142228000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2024Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
227000
CY2023Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
2384000
CY2024Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
3095000
CY2023Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
502000
CY2024Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
2354000
CY2023Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
6559000
CY2024Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18023000
CY2023Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
14271000
CY2024Q1 ntra Short Term Advances
ShortTermAdvances
7100000
CY2024Q1 ntra Short Term Advances Due Within Number Of Days
ShortTermAdvancesDueWithinNumberOfDays
P10D
CY2024Q1 ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
300000
CY2023Q1 ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
0
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11957000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
64160000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
76117000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
78646000
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2024Q1 us-gaap Lease Cost
LeaseCost
3600000
CY2023Q1 us-gaap Lease Cost
LeaseCost
3800000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4100000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
12507000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17009000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
17331000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
14264000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6633000
CY2024Q1 ntra Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
27932000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
95676000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19559000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
76117000
CY2024Q1 us-gaap Purchase Obligation
PurchaseObligation
92363000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64447000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40477000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
428000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
160000
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24242000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23412000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-007686-index-headers.html Edgar Link pending
0001558370-24-007686-index.html Edgar Link pending
0001558370-24-007686.txt Edgar Link pending
0001558370-24-007686-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20240331.xsd Edgar Link pending
ntra-20240331x10q.htm Edgar Link pending
ntra-20240331xex10d1.htm Edgar Link pending
ntra-20240331xex10d2.htm Edgar Link pending
ntra-20240331xex31d1.htm Edgar Link pending
ntra-20240331xex31d2.htm Edgar Link pending
ntra-20240331xex32d1.htm Edgar Link pending
ntra-20240331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ntra-20240331_cal.xml Edgar Link unprocessable
ntra-20240331_def.xml Edgar Link unprocessable
ntra-20240331_lab.xml Edgar Link unprocessable
ntra-20240331_pre.xml Edgar Link unprocessable
ntra-20240331x10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending